Galmed Pharmaceuticals (GLMD) Equity Ratio (2013 - 2025)

Galmed Pharmaceuticals' Equity Ratio history runs 12 years deep, the most recent figure standing at 0.85 for Q4 2025.

• In Q4 2025, Equity Ratio fell 4.0% year-over-year to 0.85; the TTM figure through Dec 2025 stood at 0.85 (down 4.0% YoY), while the FY2025 annual figure was 0.85, down 4.0% from the prior year.
• Equity Ratio was 0.85 for Q4 2025 at Galmed Pharmaceuticals, down from 0.88 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.88 in Q4 2024 to a low of 0.81 in Q4 2022.
• Historically, Equity Ratio has averaged 0.84 across 5 years, with a median of 0.83 in 2023.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio climbed 5.74% in 2024, then slipped 4.0% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.83 in 2021, then slipped by 2.71% to 0.81 in 2022, then grew by 2.97% to 0.83 in 2023, then climbed by 5.74% to 0.88 in 2024, then fell by 4.0% to 0.85 in 2025.
• The last three Equity Ratio figures came in at 0.85 (Q4 2025), 0.88 (Q4 2024), and 0.83 (Q4 2023), per Business Quant data.